BURLINGTON, Mass., June 4, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today that it has filed a registration statement with the Securities and Exchange Commission for a proposed public offering of 2,000,000 shares of its common stock. All shares proposed to be included in the offering will be sold by the company.
